IOncology

From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC 2025) was held in Vienna, the capital of music. Experts from around the world in the field of breast cancer gathered to discuss cutting-edge advancements and hotly debated topics in breast cancer diagnosis and treatment. Oncology Frontier invited Dr. Giuseppe Curigliano, the ESMO President-Elect and Associate Professor at the University of Milan and European Institute of Oncology, to share his views on the presentation topic and the outlook for curing advanced breast cancer.

Exciting news for the radiology community! Professor Valérie Vilgrain is organizing the inaugural Val d'Isère - Vilgrain Radiology Congress, set to take place from March 24-28, 2025, in the stunning…

A recent study published in the Journal of Clinical Oncology provides important insights into the prognostic role of pathogenic variants (PVs) in ATM, CHEK2, and PALB2 in breast, colorectal, and…

Urothelial carcinoma (UC) is the second most common malignancy of the urinary system, characterized by poor prognosis and low five-year survival rates. For decades, platinum-based chemotherapy has remained the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). However, limited clinical benefit and poor tolerability have left many unmet treatment needs.

The 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13 to 15 in San Francisco, California, bringing together leading experts and researchers in the field of genitourinary oncology. Among the key highlights was the final overall survival (OS) data from the TALAPRO-2 trial, presented by Dr. Neeraj Agarwal from the Huntsman Cancer Institute (HCI), University of Utah. The study drew widespread attention as it not only addressed a critical gap in first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) using a PARP inhibitor in combination with next-generation hormonal therapy (NHT) but also reinforced the growing role of precision medicine in prostate cancer treatment.

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25, showcasing the latest advances in gastrointestinal cancer research and treatment strategies. One of the most notable studies was the BREAKWATER trial (Abstract #16), which focused on BRAF V600E-mutant metastatic colorectal cancer (mCRC). This study demonstrated a significant improvement in response rates and durable efficacy, positioning EC + FOLFOX as a promising first-line treatment option for this high-risk patient group. The findings also provide further evidence for the role of precision medicine in mCRC, reinforcing the need to integrate targeted therapy into earlier treatment settings.

The Opening Session & 2025 TAT Honorary Award on March 3 set the stage for this year’s Targeted Anticancer Therapies Congress in Paris. Elena Garralda Cabanas, Cristian Massacesi, M.D., and…

Editor's Note: Nectin-4 has emerged as a highly expressed adhesion molecule in various solid tumors, becoming a popular target in recent research. 9MW2821, developed using an internationally leading ADC development…

Hepatocellular carcinoma (HCC), one of the most lethal tumors globally, has long been a research hotspot due to its complex pathogenesis involving interactions between genetics, metabolism, and viral infections. Recently, at the 2025 EASL Liver Cancer Summit held in Paris, France, a study by Professor Mohamed Abdel Samie's team from the Department of Hepatology and Gastroenterology at the National Liver Institute, Menoufia University, Egypt, revealed the crucial role of the HNF1A genotype in HCC risk. Oncology Frontier invited Professor Mohamed Abdel Samie to discuss the potential value of this gene in HCC screening and the impact of metabolic factors. We look forward to future personalized treatment strategies targeting specific genotypes bringing new breakthroughs in the prevention and treatment of HCC.

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…